PS1-5 IMpower010: Results from Asian Patients in a Phase 3 Study of Adjuvant Atezolizumab in Resected Stage IB-IIIA NSCLC

Hirotsugu Kenmotsu,Caicun Zhou,Nasser Altorki,Enriqueta Felip,Eric Vallieres,Shunichi Sugawara,Hiroshi Sakai,Haruhiro Saito,Min Tao,Koji Kawaguchi,Yunpeng Liu,Chong-Jen Yu,Qiong Wu,Huang Lin,Fan Wu,Elizabeth Bennett,Virginia Mcnally,Barbara Gitlitz,Heather Wakelee

DOI: https://doi.org/10.1016/j.annonc.2022.05.063

IF: 51.769

2022-01-01

Annals of Oncology

Abstract:The Ph 3 IMpower010 study (NCT02486718) met its primary endpoint, showing significant disease-free survival (DFS) benefit with atezo vs best supportive care (BSC) after adjuvant chemo in patients (pts) with completely resected stage II-IIIA NSCLC (HR 0.79 95% CI 0.64, 0.96), with pronounced benefit in PD-L1 TC≥1% stage II-IIIA pts (HR 0.66 95% CI 0.50, 0.88). We report data from the Asian population (pts recruited from Japan, mainland China, Taiwan, Korea and Hong Kong). Pts had completely resected stage IB (≥4 cm)-IIIA NSCLC (AJCC/UICC v7); received up to four 21-day cycles of cisplatin-based chemo; and were subsequently randomised 1:1 to atezo 1200 mg Q3W (16 cycles) or BSC. DFS (primary endpoint) was tested hierarchically in PD-L1 TC≥1% (SP263) stage II-IIIA pts, then all randomised stage II-IIIA pts, then ITT stage IB-IIIA pts. Globally, 1280 pts enrolled, 1269 received chemo and 1005 were randomised. The Asian ITT population included 233 pts; at data cutoff (21 Jan 2021), median follow-up was 32.5 mo. Baseline characteristics were generally balanced between arms. Unstratified DFS HRs (95% CI) in Asian pts were: PD-L1 TC≥1% (SP263) stage II-IIIA (n=129), 0.63 (0.37, 1.09); all randomised stage II-IIIA (n=219), 0.83 (0.55, 1.25); ITT (n=233), 0.83 (0.55, 1.25). OS data were immature in the global and Asian populations. Asian pts in the atezo arm received a median of 16 (range, 1-16) atezo doses. 95% (atezo) and 71% (BSC) of pts had any-grade AEs; events were Gr3/4 in 24% and 13%, respectively. Gr5 treatment-related AEs were reported in 0.8% of pts in the atezo arm. AEs leading to atezo discontinuation occurred in 21% of atezo-treated pts. In the IMpower010 Asian population, atezo showed DFS improvement vs BSC in PD-L1 TC≥1% (SP263) stage II-IIIA pts, consistent with the global population. The safety profile of atezo in the Asian population was consistent with that of the global population and known atezo safety profile.